Sanofi wins EU approval for Praluent anti-cholesterol drug

PARIS French drugmaker Sanofi said the European Commission had cleared its key cholesterol drug Praluent for the treatment of so-called “bad cholesterol,” or low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia.

The drug won U.S. regulatory approval in July.

(Reporting by Andrew Callus– Editing by Anand Basu)